Fujifilm is helping make the world a better, healthier, and more interesting place. Learn more about what we’re about.
Fujifilm are excited to be launching their new Mobile Mammography Unit at the International Cambridge Conference on Breast Cancer Imaging in July. The new mammography trailer will feature the AMULET Innovality, which can be used for either screening or symptomatic mammography. Dual mode tomosynthesis functionality and flexible design means the AMULET Innovality offers a single system which can be adapted for the full range of clinical mammography applications.
When launched the mobile unit will be supporting Fujifilm customers to ensure patient services are maintained during transition to a new mammography room. This will enable both training on a new system and service continuity to be provided on site, minimising disruption to both clinical staff and patients. It will also offer an inclusive approach to procurement; instead of an off-site visit which only a small number of decision makers can attend, the mobile unit can ensure that all clinicians can experience the AMULET Innovality at their site during the procurement process.
The AMULET Innovality offers design, technology and functionality which can significantly improve patient comfort. Features including the new Comfort Comp function, the Fit Sweet compression paddle, fast workflow and ergonomic design all aid the clinician in providing a more comfortable patient experience and therefore an increased likelihood of regular screening attendance. Fujifilm is passionate about improving screening rates in the UK and is committed to reducing pain and discomfort for every woman during breast cancer screening.
Fujifilm will also be holding their popular mammography workshops at the Cambridge Conference. Delegates will be invited to attend a series sessions focused on the hugely successful CEDM programme which has been established at Bangor Hospital and led by Dr Andrew Gash. Booking for the workshops can be made via the Cambridge Conference website.